abelacimab

12/01/2021 - "Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. "
12/01/2021 - "Abelacimab for Prevention of Venous Thromboembolism."
11/04/2021 - "Abelacimab for Prevention of Venous Thromboembolism. "
11/04/2021 - "Abelacimab for Prevention of Venous Thromboembolism."
11/04/2021 - "Abelacimab for Prevention of Venous Thromboembolism."

01/01/2022 - "Parenteral administration of abelacimab demonstrated a favorable safety profile with no clinically relevant bleeding events. "
12/01/2021 - "Bleeding occurred in 2%, 2%, and none of the patients in the 30-mg, 75-mg, and 150-mg abelacimab groups, respectively, and in none of the patients in the enoxaparin group. "
12/01/2021 - "Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. "

01/01/2022 - "In study ANT-004, patients with atrial fibrillation were administered monthly subcutaneous doses of abelacimab (120 mg and 180 mg), or placebo, for 3 months. "
01/01/2022 - "To investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single dose intravenous and multiple dose subcutaneous administration of abelacimab in healthy volunteers and patients with atrial fibrillation, respectively. "